These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 15371617)

  • 21. The value of dual time point (18)F-FDG PET imaging for the differentiation between malignant and benign lesions.
    Lan XL; Zhang YX; Wu ZJ; Jia Q; Wei H; Gao ZR
    Clin Radiol; 2008 Jul; 63(7):756-64. PubMed ID: 18555033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The pivotal role of FDG-PET/CT in modern medicine.
    Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
    Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combined imaging modalities: PET/CT and SPECT/CT.
    Maurer AH
    Health Phys; 2008 Nov; 95(5):571-6. PubMed ID: 18849691
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants.
    Shreve PD; Anzai Y; Wahl RL
    Radiographics; 1999; 19(1):61-77; quiz 150-1. PubMed ID: 9925392
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.
    Strobel K; Dummer R; Husarik DB; Pérez Lago M; Hany TF; Steinert HC
    Radiology; 2007 Aug; 244(2):566-74. PubMed ID: 17641374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
    Komori T; Narabayashi I; Matsumura K; Matsuki M; Akagi H; Ogura Y; Aga F; Adachi I
    Ann Nucl Med; 2007 Jun; 21(4):209-15. PubMed ID: 17581719
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pelvis: normal variants and benign findings in FDG-PET/CT imaging.
    Kohan A; Avril NE
    PET Clin; 2014 Apr; 9(2):185-93. PubMed ID: 25030281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Value of iterative reconstruction, attenuation correction, and image fusion in the interpretation of FDG PET images with an integrated dual-head coincidence camera and X-ray-based attenuation maps.
    Delbeke D; Martin WH; Patton JA; Sandler MP
    Radiology; 2001 Jan; 218(1):163-71. PubMed ID: 11152796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. (18)F-FDG PET/CT of adrenal lesions.
    Dong A; Cui Y; Wang Y; Zuo C; Bai Y
    AJR Am J Roentgenol; 2014 Aug; 203(2):245-52. PubMed ID: 25055255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical role of FDG PET in evaluation of cancer patients.
    Kostakoglu L; Agress H; Goldsmith SJ
    Radiographics; 2003; 23(2):315-40; quiz 533. PubMed ID: 12640150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of FDG-PET in the assessment of survival prognosis in melanoma.
    Pleiss C; Risse JH; Biersack HJ; Bender H
    Cancer Biother Radiopharm; 2007 Dec; 22(6):740-7. PubMed ID: 18158764
    [TBL] [Abstract][Full Text] [Related]  

  • 33. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
    Vallabhajosula S
    Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI.
    Meerwein CM; Queiroz M; Kollias S; Hüllner M; Veit-Haibach P; Huber GF
    Swiss Med Wkly; 2015; 145():w14116. PubMed ID: 25701645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Spectrum of Physiologic and Pathologic Skeletal Muscle (18)F-FDG Uptake on PET/CT.
    Karunanithi S; Soundararajan R; Sharma P; Naswa N; Bal C; Kumar R
    AJR Am J Roentgenol; 2015 Aug; 205(2):W141-9. PubMed ID: 26001118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography/computed tomography.
    Townsend DW
    Semin Nucl Med; 2008 May; 38(3):152-66. PubMed ID: 18396176
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
    Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
    J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ; Zhang YX; Wei H; Jia Q
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2253-6. PubMed ID: 18001544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management.
    Bar-Shalom R; Yefremov N; Guralnik L; Gaitini D; Frenkel A; Kuten A; Altman H; Keidar Z; Israel O
    J Nucl Med; 2003 Aug; 44(8):1200-9. PubMed ID: 12902408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.